Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib or entrectinib versus durvalumab after chemoradiotherapy in biomarker-selected unresectable stage III NSCLC
NL-OMON58795Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of alectinib, entrectinib and durvalumab in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Roche. Primary endpoint: Progression-free survival. Started Jul 2024; status: completed.
02
Drugs
alectinibentrectinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON58795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58795.